https://pioneerinstitute.org/wp-content/uploads/Red-and-Dark-Sienna-Music-Poster-9.png 512 1024 Joshua Archambault https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Joshua Archambault2021-06-03 05:45:332021-06-03 05:45:33Ten Health Policy Changes That Should Outlive COVID-19
A new study published by Pioneer Institute recommends ten healthcare reforms allowed during COVID-19 that should remain in effect permanently, after the state's emergency declaration for COVID-19 ends on June 15. These reforms have enhanced flexibility in the healthcare system, highlighting barriers that make the system more expensive, harder to access and less patient-centered.
https://pioneerinstitute.org/wp-content/uploads/Copy-of-Science-Education-Resources-During-COVID-19-1.png 512 1024 David Clancy https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png David Clancy2021-05-12 05:54:312021-05-12 05:54:31A Brighter COVID Dashboard: State Should Cut Confusion And Clarify All Eldercare Cases and Deaths
Over time, the Massachusetts Executive Office of Health and Human…
https://pioneerinstitute.org/wp-content/uploads/The-QALY-and-Cancer-Treatments_-An-Ill-Advised-Match.png 512 1024 William Smith https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png William Smith2021-04-06 06:00:112021-07-19 10:42:38The QALY and Cancer Treatments: An Ill-Advised Match
This report examines the alarming methodological and contextual shortcomings of the Quality Adjusted Life Years (QALY)-based methodology in evaluating new cancer therapies. It reveals five specific problems with ICER’s evaluation of cancer treatments and demonstrates the urgent need to prohibit the use of the QALY amid trends in rapid cancer innovations and personalized medicine.
https://pioneerinstitute.org/wp-content/uploads/HHS-COVID-FuNDiNG-Tracker-2.png 512 1024 Joshua Archambault https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Joshua Archambault2021-01-25 21:43:372021-01-25 21:44:11Direct Health Care Agreements: A New Option for Patient-Centered Care That Costs Less and Reduces Provider Burnout
Especially in the COVID era, many are looking to alleviate the increased burden on the healthcare system. One solution is direct healthcare (DHC), which can provide more patient-centered care at affordable prices and is an effective model to increase access to care for the uninsured, underinsured and those on public programs like Medicaid. This paper aims to explain the possible benefits of DHCs, often using DPCs as an example, as they have built a successful record around the country and in Massachusetts.
https://pioneerinstitute.org/wp-content/uploads/Five-Reasons-Why-Drug-Rebates-Are-Harmful-to-Patients-and-to-the-Healthcare-System-8.png 512 1024 Barbara Anthony https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Barbara Anthony2020-10-28 07:29:142020-10-28 07:29:14Healthcare Price Transparency in Massachusetts: Results from a survey of Massachusetts consumers regarding healthcare price transparency
In June 2019, Pioneer Institute, with support from Blue Cross Blue Shield of Massachusetts and the Massachusetts Association of Health Plans, contracted with noted pollster David Paleologos, head of DAPA Research at Suffolk University’s Research Bureau, to conduct a valid and reliable survey of Massachusetts consumers with employer sponsored health insurance. The goals of the survey were to determine consumers’ awareness, attitudes, views, usage, and knowledge of healthcare prices. This white paper presents analysis of the results.
https://pioneerinstitute.org/wp-content/uploads/Five-Reasons-Why-Drug-Rebates-Are-Harmful-to-Patients-and-to-the-Healthcare-System-4.png 512 1024 Gunnar Esiason https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Gunnar Esiason2020-10-20 11:20:052020-10-20 11:20:05Antimicrobial Resistance: Learning from the current global health crisis to prevent another one
The world was blindsided by COVID-19, but a new study finds that…
https://pioneerinstitute.org/wp-content/uploads/Five-Reasons-Why-Drug-Rebates-Are-Harmful-to-Patients-and-to-the-Healthcare-System.png 512 1024 William Smith https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png William Smith2020-09-01 06:38:252020-09-01 06:38:25Five Reasons Why Drug Rebates Are Harmful to Patients and to the Healthcare System
Ever-larger rebates are distorting the market for branded drugs and producing outcomes that often benefit neither consumers nor the healthcare system, according to a new study published by Pioneer Institute.
https://pioneerinstitute.org/wp-content/uploads/HHS-COVID-FuNDiNG-Tracker-1.png 512 1024 Barbara Anthony https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Barbara Anthony2020-08-10 07:52:402021-02-15 16:08:15Analysis of Spending on Shoppable Services in Massachusetts
This report reveals that consumers in just one Massachusetts county could have saved nearly $22 million in a single year and $116.6 million adjusted for inflation over four years if they switched from using the most expensive providers for 16 shoppable healthcare services to those whose prices were closer to average.
https://pioneerinstitute.org/wp-content/uploads/credit-card-6-1.png 512 1024 Barbara Anthony https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Barbara Anthony2020-06-28 10:36:132020-07-01 10:39:08Open Letter: COVID-19 Study and Recommendations Task Force established pursuant to Massachusetts Bill H.4672
Recently, Governor Baker signed legislation, H. 4672, that would create a Covid-19 task force, appointed by the legislature, to study and make recommendations to the general court that address health disparities among certain populations based on certain characteristics, including age, and which also asks the future task force to recommend other impacted populations for further study. Pioneer has prepared a public letter to that future task force that contains a list of specific recommendations regarding Covid-19 and the state’s nursing homes.
https://pioneerinstitute.org/wp-content/uploads/credit-card-5.png 512 1024 William Smith https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png William Smith2020-05-21 15:11:042020-06-29 13:05:55The Negative Impact of COVID-19 Upon the Biopharmaceutical Sector
Contrary to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new Pioneer Institute study finds many companies will emerge from the pandemic commercially weaker, dealing with delays in new product launches and with fewer resources to invest in research and development.
https://pioneerinstitute.org/wp-content/uploads/credit-card-8.png 512 1024 Barbara Anthony https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Barbara Anthony2020-05-07 15:28:302020-06-29 13:09:34Status of Healthcare Price Transparency across the United States
At a time when the coronavirus pandemic has caused massive shifts in state policies on telehealth and scope of practice in healthcare, a new Pioneer Institute study underscores that most of the 50 states continue to suffer from weak laws regarding price transparency. The study identified states that have laws that require carriers, providers or both to provide personalized cost information to consumers before obtaining healthcare services.
https://pioneerinstitute.org/wp-content/uploads/credit-card-13.png 512 1024 Barbara Anthony https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Barbara Anthony2020-04-15 16:01:162020-06-24 19:06:42The Massachusetts Crises Of Care Guidelines Need Re-Thinking
This new study contends that the Massachusetts Department of Public Health’s (DPH’s) Crises Standards of Care (CSC) issued earlier this month bear the earmarks of a state bureaucratic effort. The guidelines need to be rethought under a process that includes a thorough vetting by Massachusetts citizens.
https://pioneerinstitute.org/wp-content/uploads/health-costs.jpg 675 1200 David Paleogolos https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png David Paleogolos2019-11-04 10:05:112020-06-29 13:28:50Massachusetts Consumer Healthcare Price Transparency Survey
This public opinion survey, conducted by renowned pollster David Paleologos, Director of Suffolk University’s Research Bureau, focused on consumers’ view of healthcare price transparency. The poll showed that consumers want to know the price of care before obtaining it, and identified opportunities to improve consumers’ search for high-value, low-cost healthcare services.
https://pioneerinstitute.org/wp-content/uploads/Biotechnology.jpg 380 542 William Smith https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png William Smith2019-06-21 10:31:012020-06-29 13:34:53Looming Challenges for ICER in Assessing the Value of Rare Disease Therapies
This report examines why the Institute for Clinical and Economic Review (ICER) and the Quality Adjusted Life Years (QALY) approach to value assessment is particularly ill-suited to assess the cost-effectiveness of orphan and rare disease treatments, which represent a rapidly growing sector of the biopharmaceutical marketplace.
https://pioneerinstitute.org/wp-content/uploads/senior-man-getting-MRI1.jpg 1526 2290 Barbara Anthony https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Barbara Anthony2019-02-01 15:12:362020-06-29 13:54:57Wildly Varying MRI Prices at Massachusetts Hospitals: Why We Need Access to Healthcare Prices at All Levels
New study finds there is little correlation between a patient’s out-of-pocket cost and either the amount insurers pay or the overall price of a procedure at 14 representative Massachusetts hospitals.
https://pioneerinstitute.org/wp-content/uploads/27854267179_5d8dc9c17f_o-1.jpg 1851 2777 William Smith https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png William Smith2019-01-24 15:43:242020-06-29 13:55:46Key Questions for Legislators on the Institute for Clinical and Economic Review (ICER)
As states continue to grapple with prescription drug costs, a new Pioneer Institute study lays out the key ethical, methodological and disease-specific questions policy makers should address before deciding whether to contract with the Institute for Clinical and Economic Review (ICER) to conduct cost effectiveness reviews used to make decisions about the purchase of medicines and other medical innovations.
https://pioneerinstitute.org/wp-content/uploads/credit-card-24.png 512 1024 William Oliver https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png William Oliver2018-10-22 16:26:392020-06-29 14:07:18MassHealth Protecting Medicaid Resources for the Most Vulnerable
This report finds that Massachusetts' enhanced eligibility verification has allowed MassHealth, the Commonwealth’s Medicaid program, to save significant resources that could be redirected to the care of truly needy Medicaid recipients.
https://pioneerinstitute.org/wp-content/uploads/pile-of-red-pills.jpg 2118 1418 William Smith https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png William Smith2018-07-26 14:22:262020-06-29 14:24:30Will New England See Lower Prices from Drug Pricing Transparency Legislation?
This report finds that most new drug pricing transparency laws do not lower consumer out-of-pocket costs, and that expensive and onerous compliance rules would likely put upward pressure on prices. The report reviews recent New England legislative attempts to reduce costs by requiring the disclosure of wholesale drug prices and other information about industry pricing practices.
https://pioneerinstitute.org/wp-content/uploads/MRI.jpg 1718 2416 Scott Haller https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Scott Haller2018-07-18 14:24:562020-06-29 14:27:09Need an MRI? In Worcester, Patients Pay Less for More
Data from the Massachusetts Center for Health Information and Analysis (CHIA) show wide variations in the prices agreed to between individual insurers and providers, the portion paid by insurers and the amount that is consumers’ responsibility to pay.
https://pioneerinstitute.org/wp-content/uploads/credit-card-1-1.png 512 1024 Barbara Anthony https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Barbara Anthony2018-04-18 15:05:332020-06-29 15:08:12MA Health Insurers Have Improved Their Consumer Price Transparency Efforts, But Significant Work Remains
This study finds some significant improvements in the online cost estimator tools created by Massachusetts’ three largest health insurers, but there is much still to be done for the carriers to maximize the opportunity price transparency represents.
https://pioneerinstitute.org/wp-content/uploads/credit-card-17.png 512 1024 Jim Stergios https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Jim Stergios2017-10-23 16:05:162020-06-29 16:09:07Recommendations of Pioneer Institute to the Special Senate Committee on Health Care Cost Containment and Reform
Jim Stergios, on behalf of the Pioneer Institute, provides public…
https://pioneerinstitute.org/wp-content/uploads/dental.jpg 312 640 Jim Stergios https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Jim Stergios2017-09-12 16:26:322020-06-29 16:28:13Testimony in Support of Expanded Access to Oral Health
There is a bill before the Massachusetts Legislature seeking to expand access to dental care through the creation of a mid-level provider position, commonly known as a dental therapist.
https://pioneerinstitute.org/wp-content/uploads/telemedicine.jpg 627 900 Scott Haller https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Scott Haller2017-07-01 16:29:262020-06-29 16:31:06Dialing up Telemedicine
Massachusetts should more aggressively embrace telemedicine, which can reduce healthcare costs, increase patient satisfaction, and is more convenient for both patients and physicians.
https://pioneerinstitute.org/wp-content/uploads/credit-card-7-1.png 512 1024 Joshua Archambault https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Joshua Archambault2017-05-17 16:46:552020-06-29 16:48:58What Massachusetts Should Do in an Uncertain Healthcare World
Regardless of what happens in the debate over repealing and replacing the ACA in D.C., Massachusetts has to tackle health care costs intelligently. We need to do more than provide insurance; we need to increase access to care. That means thinking seriously about the role of private market insurers, insurance regulations and the regulation of medical providers.
https://pioneerinstitute.org/wp-content/uploads/credit-card-8-1.png 512 1024 Barbara Anthony https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Barbara Anthony2017-05-04 16:49:492020-06-29 16:51:45Lowering the Healthcare Cost Growth Benchmark
This policy brief applauds the decision by the Commonwealth of Massachusetts's Health Policy Commission to allow the benchmark for increases in the overall rate of healthcare spending to decrease this year, but urges state policy makers to remain focused on the larger culture changes that will be needed to rein in healthcare costs.
https://pioneerinstitute.org/wp-content/uploads/credit-card-6-1.png 512 1024 Barbara Anthony https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Barbara Anthony2017-05-01 16:43:322020-06-29 16:45:45Counter Point What Massachusetts Should Do As Uncertainty Engulfs US Healthcare System
Regardless of what takes place at a national level, Massachusetts has its own set of challenges to continue pursuing the state’s commitment to universal coverage at affordable prices. This report offers a ten-point program that the state should vigorously focus on in the days ahead.
https://pioneerinstitute.org/wp-content/uploads/caretakers-e1557953012328.jpg 534 750 Barbara Anthony https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Barbara Anthony2017-04-10 10:44:222020-07-01 10:46:16Massachusetts Hospitals Score Poorly on Price Transparency…Again
Eighteen months after an initial survey of prices at hospitals in Massachusetts, Pioneer Institute conducted a follow-up survey of all but one of the hospitals from the first survey to see if there had been any change in the performance of these institutions since their last assessment. Initial survey calls were conducted between September 20th and November 2nd, 2016.
https://pioneerinstitute.org/wp-content/uploads/credit-card-7-1.png 512 1024 Jim Stergios https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Jim Stergios2017-02-17 10:59:092020-07-01 11:01:15Recommendations to the Transparency Subcommittee of the Special Commission on Provider Variation
Submitted to the Special Commission on Provider Price Variation on January 31, 2017
https://pioneerinstitute.org/wp-content/uploads/Price-cut-20-dollar-bill-with-scissors.jpg 2336 3504 Barbara Anthony https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Barbara Anthony2016-10-17 12:32:512020-07-01 12:34:58Testimony on Healthcare Price Transparency
Testimony emphasized the need to focus more on what would help consumers make better decisions about spending on healthcare.
https://pioneerinstitute.org/wp-content/uploads/credit-card-1-2.png 512 1024 Barbara Anthony https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Barbara Anthony2016-10-13 12:43:202020-07-01 12:46:03Transparency in Retail Drug Prices: Easy to Obtain but Accuracy May Be Doubtful
This paper is the fourth in a series on price transparency in the healthcare industry, and the first Pioneer report to focus on the retail price of prescription medications. Researchers called 44 retail drug stores across the state asking for the price of a 30-day supply of each drug in a common dosage. In each case the callers said they were self-pay and pressed the drug store for information about discounts.